PMID- 30136315
OWN - NLM
STAT- MEDLINE
DCOM- 20191129
LR  - 20191129
IS  - 1399-0012 (Electronic)
IS  - 0902-0063 (Print)
IS  - 0902-0063 (Linking)
VI  - 32
IP  - 10
DP  - 2018 Oct
TI  - The impact of human leukocyte antigen donor and recipient serotyping and matching 
      on liver transplant graft failure in primary sclerosing cholangitis, autoimmune 
      hepatitis, and primary biliary cholangitis.
PG  - e13388
LID - 10.1111/ctr.13388 [doi]
AB  - Human leukocyte antigen (HLA) serotyping is not considered to have significant 
      impact on liver graft survival and does not factor into U.S. organ allocation. 
      Immune-related liver diseases such as primary sclerosing cholangitis (PSC), 
      autoimmune hepatitis (AIH), and primary biliary cholangitis (PBC) have been 
      speculated to represent a disease subgroup that may have significantly different 
      graft outcomes depending on HLA donor/recipient characterization. The aim of this 
      study was to investigate whether HLA serotyping/matching influenced 
      post-transplant graft failure for immune-related liver diseases using the United 
      Network for Organ Sharing database. From 1994 to 2015, 5665 patients underwent 
      first-time liver-only transplants for PSC, AIH, and PBC with complete graft 
      survival and donor/recipient HLA data. Graft failure was noted in 38.6% 
      (2188/5665), and all groups had comparable 5-year graft survival (75.1%-78.8%, 
      P = 0.069). The overall degree of, and loci-specific mismatch level, did not 
      influence outcomes. Multivariable Cox proportional hazards regression noted 
      increased graft failure risk for recipient HLA-B7, HLA-B57, HLA-B75, HLA-DR13 and 
      donor HLA-B55, HLA-B58, and HLA-DR8 for PSC patients, protective effects for 
      recipient HLA-DR1 and HLA-DR3 for AIH patients, and increased risk for HLA-DR7 
      for AIH patients. These findings warrant further investigation to evaluate the 
      impact of HLA serotyping on post-transplant outcomes.
CI  - (c) 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Patel, Yuval A
AU  - Patel YA
AUID- ORCID: 0000-0002-4362-3983
AD  - Division of Gastroenterology, Department of Medicine, Duke University School of 
      Medicine, Durham, North Carolina.
FAU - Henson, Jacqueline B
AU  - Henson JB
AD  - Duke University School of Medicine, Durham, North Carolina.
FAU - Wilder, Julius M
AU  - Wilder JM
AD  - Division of Gastroenterology, Department of Medicine, Duke University School of 
      Medicine, Durham, North Carolina.
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, 
      North Carolina.
FAU - Zheng, Jiayin
AU  - Zheng J
AD  - Department of Biostatistics and Bioinformatics, Duke University School of 
      Medicine, Durham, North Carolina.
FAU - Chow, Schein-Chung
AU  - Chow SC
AD  - Department of Biostatistics and Bioinformatics, Duke University School of 
      Medicine, Durham, North Carolina.
FAU - Berg, Carl L
AU  - Berg CL
AD  - Division of Gastroenterology, Department of Medicine, Duke University School of 
      Medicine, Durham, North Carolina.
FAU - Knechtle, Stuart J
AU  - Knechtle SJ
AUID- ORCID: 0000-0002-1625-385X
AD  - Duke Transplant Center, Department of Surgery, Duke University Medical Center, 
      Durham, North Carolina.
FAU - Muir, Andrew J
AU  - Muir AJ
AD  - Division of Gastroenterology, Department of Medicine, Duke University School of 
      Medicine, Durham, North Carolina.
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, 
      North Carolina.
LA  - eng
GR  - T32 DK007568/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20180915
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Case-Control Studies
MH  - Cholangitis, Sclerosing/*immunology/surgery
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Rejection/*immunology
MH  - Graft Survival
MH  - HLA Antigens/*immunology
MH  - Hepatitis, Autoimmune/*immunology/surgery
MH  - Histocompatibility/*immunology
MH  - Humans
MH  - Liver Cirrhosis, Biliary/*immunology/surgery
MH  - *Liver Transplantation
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
MH  - Serotyping
MH  - Tissue Donors/supply & distribution
MH  - Tissue and Organ Procurement
PMC - PMC6834112
MID - NIHMS1048181
OTO - NOTNLM
OT  - autoimmune hepatitis
OT  - human leukocyte antigen
OT  - liver transplant
OT  - primary biliary cholangitis
OT  - primary sclerosing cholangitis
COIS- CONFLICT OF INTEREST None.
EDAT- 2018/08/24 06:00
MHDA- 2019/11/30 06:00
PMCR- 2019/11/06
CRDT- 2018/08/24 06:00
PHST- 2017/11/21 00:00 [received]
PHST- 2018/07/11 00:00 [revised]
PHST- 2018/08/16 00:00 [accepted]
PHST- 2018/08/24 06:00 [pubmed]
PHST- 2019/11/30 06:00 [medline]
PHST- 2018/08/24 06:00 [entrez]
PHST- 2019/11/06 00:00 [pmc-release]
AID - 10.1111/ctr.13388 [doi]
PST - ppublish
SO  - Clin Transplant. 2018 Oct;32(10):e13388. doi: 10.1111/ctr.13388. Epub 2018 Sep 
      15.